TSTickerStarGet alerts

Clearmind completes enrollment for Part C of CMND-100 Phase I/IIa trial

Clearmind Medicine announced that patient enrollment was completed for Part C of its CMND-100 Phase I/IIa clinical trial. Part C is a randomized, double-blind, placebo-controlled multiple-dose study evaluating safety, tolerability and pharmacokinetics at sites in the United States and Israel. The announcement did not include financial results or guidance.

Share this story

Key takeaways

  • Enrollment status: Patient enrollment for Part C of the CMND-100 Phase I/IIa trial was completed.

  • Study design: Part C is randomized, double-blind, placebo-controlled and multiple-dose, assessing safety, tolerability and pharmacokinetics.

  • Trial locations: The study is being conducted at clinical research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center.

  • Earlier cohorts: Part C follows enrollment of the first cohort in Part B, the first evaluation of CMND-100 in patients with moderate-to-severe alcohol use disorder, and builds on Part A safety and tolerability data in healthy volunteers.

  • Expected data use: The company expects Part C data to further inform its understanding of CMND-100's safety, tolerability and pharmacokinetic profile and support advancement toward future development milestones.

  • Intellectual property: The portfolio consists of nineteen patent families, including 32 granted patents; the company intends to seek additional patents and may acquire additional intellectual property.

  • Financial disclosure: The exhibit did not report revenue, earnings, cash flow or financial guidance.

Key metrics

CMND-100 Phase I/IIa Part C patient enrollment
Completed
Patent familiesNovember 16, 2026
19 patent families
Granted patentsNovember 16, 2026
32 granted patents

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow CMND in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert